Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only Get Premium

NWBO Northwest Biotherapeutics Inc

Price (delayed)

$0.265

Market cap

$380.99M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.07

Enterprise value

$447.21M

Highlights
Northwest Biotherapeutics's revenue has increased by 10% YoY and by 7% QoQ
The company's gross profit rose by 10% YoY and by 7% QoQ
NWBO's debt is up by 41% YoY and by 2.3% QoQ
The equity has contracted by 36% YoY and by 5% from the previous quarter

Key stats

What are the main financial stats of NWBO
Market
Shares outstanding
1.44B
Market cap
$380.99M
Enterprise value
$447.21M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
244.58
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
303.61
Earnings
Revenue
$1.47M
Gross profit
$1.47M
Operating income
-$68.08M
Net income
-$84.81M
EBIT
-$76.96M
EBITDA
-$74.92M
Free cash flow
-$54.9M
Per share
EPS
-$0.07
EPS diluted
-$0.07
Free cash flow per share
-$0.04
Book value per share
-$0.07
Revenue per share
$0
TBVPS
$0.02
Balance sheet
Total assets
$27.51M
Total liabilities
$112.34M
Debt
$69.01M
Equity
-$99.48M
Working capital
-$78.37M
Liquidity
Debt to equity
-0.69
Current ratio
0.06
Quick ratio
0.03
Net debt/EBITDA
-0.88
Margins
EBITDA margin
-5,086.3%
Gross margin
100%
Net margin
-5,757.6%
Operating margin
-4,621.5%
Efficiency
Return on assets
-307.5%
Return on equity
N/A
Return on invested capital
-401.8%
Return on capital employed
N/A
Return on sales
-5,224.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NWBO stock price

How has the Northwest Biotherapeutics stock price performed over time
Intraday
16.48%
1 week
10.79%
1 month
-4.64%
1 year
-32.91%
YTD
-3.57%
QTD
10.46%

Financial performance

How have Northwest Biotherapeutics's revenue and profit performed over time
Revenue
$1.47M
Gross profit
$1.47M
Operating income
-$68.08M
Net income
-$84.81M
Gross margin
100%
Net margin
-5,757.6%

NWBO financials

NWBO's net income is down by 21% year-on-year
NWBO's operating income is down by 17% YoY and by 2.4% from the previous quarter
Northwest Biotherapeutics's revenue has increased by 10% YoY and by 7% QoQ
The company's gross profit rose by 10% YoY and by 7% QoQ

Price vs fundamentals

How does NWBO's price correlate with its fundamentals

NWBO Price vs fundamentals

NWBO Earnings waterfall

NWBO Price vs fair value

Growth

What is Northwest Biotherapeutics's growth rate over time

NWBO growth chart

Valuation

What is Northwest Biotherapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
244.58
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
303.61

Valuation vs average

Price to earnings (P/E)

The EPS has contracted by 17% YoY

Price to book (P/B)

The equity has contracted by 36% YoY and by 5% from the previous quarter

Price to sales (P/S)

The P/S is 60% below the 5-year quarterly average of 528.0 and 18% below the last 4 quarters average of 255.8
Northwest Biotherapeutics's revenue has increased by 10% YoY and by 7% QoQ

Efficiency

How efficient is Northwest Biotherapeutics business performance
The return on assets has declined by 24% year-on-year
The ROS has contracted by 8% YoY but it has grown by 5% from the previous quarter
The ROIC has decreased by 4% QoQ but it has increased by 2.5% YoY

Dividends

What is NWBO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NWBO.

Financial health

How did Northwest Biotherapeutics financials performed over time

Assets vs liabilities

The total assets is 76% smaller than the total liabilities
NWBO's total liabilities is up by 37% year-on-year and by 6% since the previous quarter
Northwest Biotherapeutics's quick ratio has decreased by 25% YoY

Debt vs equity

NWBO's debt is 169% higher than its equity
NWBO's debt is up by 41% YoY and by 2.3% QoQ
The equity has contracted by 36% YoY and by 5% from the previous quarter

Balance sheet

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.